Limits...
Efficacy of topical mesenchymal stem cell therapy in the treatment of experimental dry eye syndrome model.

Beyazyıldız E, Pınarlı FA, Beyazyıldız O, Hekimoğlu ER, Acar U, Demir MN, Albayrak A, Kaymaz F, Sobacı G, Delibaşı T - Stem Cells Int (2014)

Bottom Line: Purpose.Eye drops containing either bromodeoxyuridine labeled MSCs (n = 9) or phosphate buffer solution (n = 7) were topically applied once daily for one week.Topical application of MSCs could be a safe and effective method for the treatment of DES and could potentially be used for further clinical research studies.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Samsun Research and Training Hospital, Kıranköy Mevkii, 55100 Samsun, Turkey.

ABSTRACT
Purpose. The current study was set out to address the therapeutic efficacy of topically applied mesenchymal stem cells (MSCs) on dry eye syndrome (DES) induced by benzalkonium chloride (BAC) in rats. Methods. Rats were divided into two groups just after establishment of DES. Eye drops containing either bromodeoxyuridine labeled MSCs (n = 9) or phosphate buffer solution (n = 7) were topically applied once daily for one week. Schirmer test, break-up time score, ocular surface evaluation tests, and corneal inflammatory index scoring tests were applied to all rats at baseline and after treatment. All rats were sacrificed after one week for histological and electron microscopic analysis. Results. Mean aqueous tear volume and tear film stability were significantly increased in rats treated with MSCs (P < 0.05). Infiltration of bromodeoxyuridine labeled MSCs into the meibomian glands and conjunctival epithelium was observed in MSCs treated rats. Increased number of secretory granules and number of goblet cells were observed in MSCs treated rats. Conclusion. Topical application of MSCs could be a safe and effective method for the treatment of DES and could potentially be used for further clinical research studies.

No MeSH data available.


Related in: MedlinePlus

BrdU labeled MSCs were shown to infiltrate the meibomian glands and conjunctival epithelium. (a) Meibomian gland infiltration of BrdU labeled MSCs. Cells with BrdU+ stained nucleus (red arrows). Spread of BrdU stained areas to the cytoplasm of some cells (yellow arrow). (b) BrdU+ cells in the conjunctival epithelium (red arrow) (Leica HMLB45: Germany, 2000; magnification: ×400).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4127226&req=5

fig6: BrdU labeled MSCs were shown to infiltrate the meibomian glands and conjunctival epithelium. (a) Meibomian gland infiltration of BrdU labeled MSCs. Cells with BrdU+ stained nucleus (red arrows). Spread of BrdU stained areas to the cytoplasm of some cells (yellow arrow). (b) BrdU+ cells in the conjunctival epithelium (red arrow) (Leica HMLB45: Germany, 2000; magnification: ×400).

Mentions: Conventional method for immunohistochemical staining has been used to quantify number of infiltrated BrdU+ cells [15, 16]. Briefly, three areas in three sections in all rats were examined at ×20 magnification and number of counted BrdU+ cells to other cells were calculated. The mean result was 6.7% in the treatment group. Topically applied MSCs mostly infiltrated into meibomian glands and conjunctival epithelium. Migration of BrdU labeled MSCs was shown in Figure 6.


Efficacy of topical mesenchymal stem cell therapy in the treatment of experimental dry eye syndrome model.

Beyazyıldız E, Pınarlı FA, Beyazyıldız O, Hekimoğlu ER, Acar U, Demir MN, Albayrak A, Kaymaz F, Sobacı G, Delibaşı T - Stem Cells Int (2014)

BrdU labeled MSCs were shown to infiltrate the meibomian glands and conjunctival epithelium. (a) Meibomian gland infiltration of BrdU labeled MSCs. Cells with BrdU+ stained nucleus (red arrows). Spread of BrdU stained areas to the cytoplasm of some cells (yellow arrow). (b) BrdU+ cells in the conjunctival epithelium (red arrow) (Leica HMLB45: Germany, 2000; magnification: ×400).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4127226&req=5

fig6: BrdU labeled MSCs were shown to infiltrate the meibomian glands and conjunctival epithelium. (a) Meibomian gland infiltration of BrdU labeled MSCs. Cells with BrdU+ stained nucleus (red arrows). Spread of BrdU stained areas to the cytoplasm of some cells (yellow arrow). (b) BrdU+ cells in the conjunctival epithelium (red arrow) (Leica HMLB45: Germany, 2000; magnification: ×400).
Mentions: Conventional method for immunohistochemical staining has been used to quantify number of infiltrated BrdU+ cells [15, 16]. Briefly, three areas in three sections in all rats were examined at ×20 magnification and number of counted BrdU+ cells to other cells were calculated. The mean result was 6.7% in the treatment group. Topically applied MSCs mostly infiltrated into meibomian glands and conjunctival epithelium. Migration of BrdU labeled MSCs was shown in Figure 6.

Bottom Line: Purpose.Eye drops containing either bromodeoxyuridine labeled MSCs (n = 9) or phosphate buffer solution (n = 7) were topically applied once daily for one week.Topical application of MSCs could be a safe and effective method for the treatment of DES and could potentially be used for further clinical research studies.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Samsun Research and Training Hospital, Kıranköy Mevkii, 55100 Samsun, Turkey.

ABSTRACT
Purpose. The current study was set out to address the therapeutic efficacy of topically applied mesenchymal stem cells (MSCs) on dry eye syndrome (DES) induced by benzalkonium chloride (BAC) in rats. Methods. Rats were divided into two groups just after establishment of DES. Eye drops containing either bromodeoxyuridine labeled MSCs (n = 9) or phosphate buffer solution (n = 7) were topically applied once daily for one week. Schirmer test, break-up time score, ocular surface evaluation tests, and corneal inflammatory index scoring tests were applied to all rats at baseline and after treatment. All rats were sacrificed after one week for histological and electron microscopic analysis. Results. Mean aqueous tear volume and tear film stability were significantly increased in rats treated with MSCs (P < 0.05). Infiltration of bromodeoxyuridine labeled MSCs into the meibomian glands and conjunctival epithelium was observed in MSCs treated rats. Increased number of secretory granules and number of goblet cells were observed in MSCs treated rats. Conclusion. Topical application of MSCs could be a safe and effective method for the treatment of DES and could potentially be used for further clinical research studies.

No MeSH data available.


Related in: MedlinePlus